BidaskClub upgraded shares of Deciphera Pharmaceuticals (NASDAQ:DCPH) from a sell rating to a hold rating in a research report sent to investors on Friday morning, BidAskClub reports.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research raised Deciphera Pharmaceuticals from a sell rating to a hold rating and set a $26.00 price objective on the stock in a research note on Monday, August 5th. Leerink Swann reissued a positive rating and issued a $29.00 price objective (up previously from $20.00) on shares of Deciphera Pharmaceuticals in a research note on Wednesday, August 14th. Piper Jaffray Companies increased their price objective on Deciphera Pharmaceuticals from $50.00 to $55.00 and gave the stock an overweight rating in a research note on Monday, June 3rd. They noted that the move was a valuation call. Deutsche Bank initiated coverage on Deciphera Pharmaceuticals in a research note on Thursday, July 18th. They issued a buy rating and a $42.00 price objective on the stock. Finally, Cantor Fitzgerald increased their price objective on Deciphera Pharmaceuticals from $43.00 to $55.00 and gave the stock an overweight rating in a research note on Wednesday, August 14th. Four research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company’s stock. The company currently has a consensus rating of Buy and an average price target of $47.90.

DCPH opened at $36.65 on Friday. The stock has a market cap of $1.39 billion, a price-to-earnings ratio of -13.00 and a beta of 2.34. The stock’s 50 day moving average price is $24.22 and its 200-day moving average price is $24.58. Deciphera Pharmaceuticals has a one year low of $18.55 and a one year high of $42.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.26 and a current ratio of 7.26.

Deciphera Pharmaceuticals (NASDAQ:DCPH) last announced its quarterly earnings data on Friday, August 2nd. The company reported ($0.56) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.12) by $0.56. The firm had revenue of $25.00 million during the quarter, compared to the consensus estimate of $20.00 million. As a group, analysts predict that Deciphera Pharmaceuticals will post -4.19 earnings per share for the current fiscal year.

In other Deciphera Pharmaceuticals news, CFO Thomas Patrick Kelly sold 2,100 shares of the company’s stock in a transaction on Monday, June 3rd. The stock was sold at an average price of $25.20, for a total transaction of $52,920.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Daniel Lee Flynn sold 148,107 shares of the company’s stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $40.92, for a total value of $6,060,538.44. The disclosure for this sale can be found here. In the last three months, insiders sold 535,607 shares of company stock worth $20,283,409. 7.02% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of DCPH. Norges Bank purchased a new stake in Deciphera Pharmaceuticals during the fourth quarter worth $6,974,000. BlackRock Inc. lifted its holdings in Deciphera Pharmaceuticals by 25.6% during the second quarter. BlackRock Inc. now owns 1,531,844 shares of the company’s stock worth $34,543,000 after buying an additional 311,870 shares during the period. Dimensional Fund Advisors LP purchased a new stake in Deciphera Pharmaceuticals during the fourth quarter worth $4,337,000. Point72 Asset Management L.P. purchased a new stake in Deciphera Pharmaceuticals during the second quarter worth $4,606,000. Finally, Alps Advisors Inc. purchased a new stake in Deciphera Pharmaceuticals during the second quarter worth $1,802,000. Institutional investors own 59.80% of the company’s stock.

About Deciphera Pharmaceuticals

Deciphera Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response of various cancer therapies. The company's lead drug candidate is DCC-2618, which is in Phase III trial for the treatment of gastrointestinal stromal tumors; and that is in Phase I trial for treating advanced systemic mastocytosis, gliomas, melanoma, NSCLC/germ cell/penile, and soft tissue sarcomas.

Recommended Story: What is a growth and income fund?

Analyst Recommendations for Deciphera Pharmaceuticals (NASDAQ:DCPH)

Receive News & Ratings for Deciphera Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Deciphera Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.